A new medical collaboration between Lionheart Health, Inc. and ElectroMedical Technologies aims to transform wound care through innovative bioelectric healing technologies. The joint venture combines Lionheart's patented bioelectric signaling software with ElectroMed's advanced device technology platform, targeting critical patient needs such as preventing limb amputations. The partnership emerged from promising pilot studies demonstrating remarkable success rates in treating non-healing wounds. In previous studies conducted in the Czech Republic, Mexico, and the United States, over 90% of limbs previously scheduled for amputation were successfully saved using their techniques.
Matthew Wolfson, CEO of ElectroMed Technologies, emphasized the transformative potential of their collaboration, stating that their integrated approach could revolutionize wound care for the next century. The joint venture is particularly focused on addressing diabetic ulcers, a significant medical challenge. The upcoming clinical studies will explore multiple treatment approaches, including bioelectric stimulation alone, combined with enhanced regenerative techniques, and incorporating advanced medical technologies like amniotic membrane grafts and stem cell therapies.
With approximately 185,000 amputations occurring annually in the United States, primarily due to non-healing wounds, the joint venture has an ambitious goal of reducing these procedures by more than half within ten years. Lionheart Health's extensive patent portfolio of over 500 claims related to bioelectric protein expressions and tissue regeneration, combined with ElectroMed's 18 years of experience in electrical stimulation devices, positions the partnership at the forefront of regenerative medicine. The collaboration plans to establish 124 clinics worldwide trained in their patented bioelectric treatment protocols. Each clinic will be licensed to offer this innovative wound care technology, with the joint venture receiving a 7% gross sales royalty per patient service.
By integrating cutting-edge bioelectric stimulation, regenerative proteins, and advanced medical technologies, this partnership represents a significant leap forward in wound healing and potentially life-altering medical interventions for patients at risk of limb amputation. The implications extend beyond individual patient outcomes to broader healthcare system impacts, potentially reducing long-term disability costs and improving quality of life for hundreds of thousands of patients globally. The technology's proven success in international pilot studies suggests it could become a new standard of care for complex wound management, particularly for diabetic patients who face disproportionately high risks of limb loss.
